NEW YORK, Nov. 21, 2016 /PRNewswire/ -- Taxotere lawsuits filed on behalf of cancer patients who allegedly experienced permanent hair loss following treatment with the chemotherapy agent have begun to move forward in a multidistrict litigation recently established in the U.S. District Court, Eastern District of Louisiana. Court records indicate that the proceeding's first Status Conference was convened on November 10th, followed by the issuance of two new Orders. The first, dated November 16th, stipulates that applications for Special Counsel for Settlement Negotiations be emailed to chambers no later than December 5, 2016. A second Order dated November 17th establishes the litigation's leadership structure, including Plaintiffs' Liaison Counsel and the Plaintiffs' Steering Committee. (In Re: Taxotere (Docetaxal) Products Liability Litigation - MDL No. 2740)
"Our Firm represents breast cancer patients and others who allegedly suffered permanent hair loss following Taxotere treatment. We are pleased that this litigation is moving forward, and will continue to monitor its progress for any developments relevant to our clients' cases," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm is now offering free case reviews to breast cancer patients and others whose hair failed to grow back following chemotherapy with Taxotere.
Taxotere Hair Loss Allegations
Taxotere (docetaxel) is marketed by Sanofi-Aventis, and was initially approved to treat breast cancer. Since being approved by the U.S. Food & Drug Administration (FDA) in 1996, the chemotherapy agent has also been cleared to treat head and neck cancer, gastric cancer, prostate cancer and non-small cell lung cancer. Last December, the Taxotere label was modified to note that cases of permanent alopecia had been reported among chemotherapy patients who had been treated with the medication.
More than 180 Taxotere hair loss claims are now pending in the centralized proceeding underway in the Eastern District of Louisiana. Plaintiffs who have filed these lawsuits allege that hair loss – a common side effect of chemotherapy – is far more likely to be permanent with Taxotere compared to alternative medications that are equally effective. Plaintiffs further assert that Sanofi-Aventis has long cautioned patients and the medical community in the European Union and Canada that Taxotere could potentially cause permanent and disfiguring hair loss, even as the drug's U.S. label merely stated that "hair generally grows back" following its use.
Individuals who allegedly experienced permanent hair loss following chemotherapy with Taxotere may be eligible for compensation. To learn more about filing a Taxotere lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.
About Bernstein Liebhard LLP Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP 10 East 40th Street New York, New York 10016 800-511-5092